about
Generation of human antigen-specific monoclonal IgM antibodies using vaccinated "human immune system" miceDevelopment of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.Molecularly defined antibody conjugation through a selenocysteine interface.Host cell protein dynamics in the supernatant of a mAb producing CHO cell line.Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.Monoclonal antibodies from plants: a new speed record.Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice.On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions.Efficient antibody production upon suppression of O mannosylation in the yeast Ogataea minutaModelling cancer in human skin tissue.An engineered selenocysteine defines a unique class of antibody derivatives.Antibody therapeutics: isotype and glycoform selection.Monoclonal antibodies for prophylaxis and therapy of infectious diseases.Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies.Immunopharmacology: utilizing antibodies as ion channel modulators.State-of-the-art in downstream processing of monoclonal antibodies: process trends in design and validation.Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools.The future of monoclonal antibody technology.Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV.Targeting intracellular oncoproteins with antibody therapy or vaccination.Intracellular delivery of biomineralized monoclonal antibodies to combat viral infection.Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution.Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies.Nanomedicine Faces Barriers.Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook.Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice.Avimers hold their own.Comparison of the chromatographic properties of IgG1 and IgG2 antibody subclasses.
P2860
Q28749033-37B34010-F3CC-4A11-9F19-27807E9DBF45Q33301860-C1FCB469-233A-42FD-94A9-C395AEA893C6Q33675575-A08AF6FE-E89D-4BF8-86C7-762D5F860E3DQ34085446-4998BAC1-C64B-4821-A8E5-61D8D9446410Q34574834-68FC62FF-FF66-4855-BB19-D22E5A701F33Q35075379-094CBF91-6596-4F1E-BC8A-625F44F06E96Q35214746-19FA1CAA-AAC8-495E-A088-A10BE3EE290BQ35889827-B9C94016-FCA5-44F5-8E3E-92E5FE5E9744Q36377207-2BEA747D-ABD4-47B2-8B59-48B5C15FCA17Q36420948-41B188D0-B535-4750-9CAF-3FD27BE95000Q36422870-35375926-ED1F-4225-9313-5B453543A7B8Q36843553-4FB9F6E6-2865-4FC3-86A4-8F7705BD9121Q36922260-826FE253-5D3C-452B-8902-70BAE7D677FCQ36989900-74115804-C9BA-4789-8DA3-2BD38A75FF97Q37323537-DA51D9B4-369A-423A-96E7-17EA5DD9D408Q37960086-BE15CC95-DCFB-4603-8E32-1B04F1D0BE87Q38013999-F3648729-7FAC-44D8-8D85-067944116529Q38313350-858913BA-D021-46ED-BED2-DF74B5035CB0Q38561633-324C81A3-6BF3-4373-BF77-284972216373Q38688524-6566B7BA-A7C8-415E-A35E-1A8162FD7320Q39477768-2B1500CD-8294-4C0E-982B-2DA01F328EB7Q40869471-585CAE29-CE58-46F8-80D4-E467469EB61DQ42108007-70FEA534-1F6B-452E-8D95-C8E7ED35D95CQ43070206-D552AC01-E5DB-49EC-8025-05F16A34122EQ46181824-6E5D9CBF-3A84-45D2-BBED-A15AF537A0B0Q47135878-10270EF0-1A0E-4987-8E88-60ED0727C939Q51076481-0F4FAE92-198B-4161-A8F0-9B75D8611AB1Q51308473-D4597F79-FC3E-4923-BAC4-9ACEFE3E1577Q51771638-5E2CB49B-2C38-4C87-A66E-6089967BB585
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Upping the ante on antibodies.
@en
Upping the ante on antibodies.
@nl
type
label
Upping the ante on antibodies.
@en
Upping the ante on antibodies.
@nl
prefLabel
Upping the ante on antibodies.
@en
Upping the ante on antibodies.
@nl
P356
P1433
P1476
Upping the ante on antibodies.
@en
P2888
P304
P356
10.1038/NBT0905-1065
P50
P577
2005-09-01T00:00:00Z